FDA Approves Takeda’s ENTYVIO Biologics Application for Pediatric UC and Crohn’s Disease
The U.S. Food and Drug Administration has officially cleared Takeda Pharmaceutical’s supplementary Biologics License Application (SBLA) for intravenous ENTYVIO (vedolizumab) targeting pediatric ulcerative colitis and Crohn’s disease. A PDUFA date has been scheduled for the first quarter of 2027.
This milestone highlights ENTYVIO’s expanded indication to children aged 2 years and older, building on the established safety and efficacy data from large-scale pediatric trials. The approval paves the way for accelerated market entry and potential global expansion.
ENTYVIO is positioned as a transformative therapy for moderate to severe cases of UC and Crohn’s disease, offering a new option for families affected by these chronic conditions. Takeda remains committed to advancing this important treatment until it reaches patients worldwide.
For further updates on biotech innovations and regulatory developments, continue exploring reputable health and science sources.
